Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoVista Innovative Therapies has announced the appointment of Wolfram Rodatz as CEO of AdnaGen, effective April 1, 2008.
Subscribe to our email newsletter
Prior to joining AdnaGen, Dr Rodatz was general manager of Digilab BioVisioN, a Germany company offering technologies for peptide and protein biomarker discovery as well as sample preparation services and products.
OncoVista Innovative Therapies currently owns 85% of AdnaGen, a privately-held German diagnostic company that has developed and commercialized proprietary technology and kits for the sensitive detection and molecular analysis of circulating tumor cells in blood.
Alexander Weis OncoVista’s CEO, said: “Dr Rodatz will be of great value in successfully managing and marketing AdnaGen’s innovative and unique tumor diagnostic products and his leadership in this area will be instrumental in accelerating corporate growth at OncoVista.”